NeuroVive Presents Positive Preclinical Data in Hepatocellular Cancer at HCC Summit
LUND, Sweden, Jan. 19, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer data related to the company's sanglifehrin-based compounds has been accepted for present...
NeuroVive Signs Collaboration Agreement With Karolinska Institutet
LUND, Sweden, Jan. 10, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that a collaboration agreement has been signed withKarolinska Institutet, Stockholm, Sweden, regarding development of the company's co...
NeuroVive to Present at the 9th Annual Biotech Showcase Conference
LUND, Sweden, Jan. 3, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the company is scheduled to present the 9th Annual Biotech Showcase Conference heldJanuary 9-11, 2017 in San Francisco, U.S. Durin...
